Proteon Therapeutics

Proteon Therapeutics
Industry Pharmaceuticals

Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.

It is developing PRT-201, a drug to improve blood flow following vascular surgery procedures, and, more broadly, is interested in vascular access for hemodialysis and peripheral arterial disease (PAD). On September 10, 2008, Proteon announced that the Food and Drug Administration had granted fast track status to PRT-201.

Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University. Major investors in the company include MPM Capital, Rockhill Partners, TVM Capital, Skyline Ventures, Prism VentureWorks, Vectis Life Sciences and Intersouth Partners. They have invested over $72 million in the company.[1]

On March 5, 2009, the company announced that it had raised $32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to $550 million.[2]


  1. Roberts, Rob (April 5, 2007). "Proteon secures $12M in financing". Kansas City Business Journal. Retrieved 2008-07-27.
  2. "Proteon raises $38m, signs option deal with Novartis". The Boston Globe. March 5, 2009.

External links

This article is issued from Wikipedia - version of the 5/31/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.